Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS
- Conditions
- Non ST Segment Elevation Acute Coronary SyndromeCoronary Artery DiseasePercutaneous Coronary Intervention
- Registration Number
- NCT05202041
- Lead Sponsor
- Wuhan Asia Heart Hospital
- Brief Summary
This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The purpose of this study is to investigate the diagnostic performance and prognostic ability of AccuFFRangio for non-IRA in NSTE-ACS patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- 18 Years and older
- Non-ST-segment elevation acute coronary syndrome patients with at least 1 non-IRA
- Diameter stenosis of 50%-90% by visual estimate
- Reference vessel size > 2 mm in stenotic segment by visual estimate
- LVEF ≤ 40%
- eGFR < 60 mL/min
- Allergy to contrast media, adenosine
- Prior CABG
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Vessel-oriented composite endpoints (VOCEs) 1 year Composite of vessel-related cardiovascular death, vessel-related myocardial infarction, and ischemia-driven target vessel revascularization.
Post-PCI AccuFFRangio 1 year AccuFFRangio limits to yield no VOCEs.
- Secondary Outcome Measures
Name Time Method Cost analysis 1 year Cost savings of AccuFFRangio-guided strategy.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.